The model discusses in detail the impact of COVID-19 on NGS Tests market for the year 2020 and beyond. NGS allows an entire genome to be sequenced at once by fragmenting DNA and sequencing those fragments in an automated, parallel manner. NGS can be used for whole-genome sequencing, exome sequencing, transcriptome sequencing (RNA sequencing), and targeted sequencing of multigene panels.

It is now standard to test for a high number of mutations to personalize treatment decisions, use of NGS panels that can evaluate tumour biopsies for a wide range of potentially targetable mutations is increasing. NGS is routinely being used to identify KRAS, BRAF, EGFR, ALK, BRCA and HER2 mutations.

This model includes Next Generation Sequencing (NGS) Tests.

Scope
Who should buy this report?

This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for:

CMO executives who must have deep understanding of the Next Generation Sequencing (NGS) Tests market place to make strategic planning and investment decisions.

Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.

Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Key Highlights
Competitive Assessment

Currently marketed Next Generation Sequencing (NGS) Tests and evolving competitive landscape:

Insightful review of the key industry trends.

Annualized total Next Generation Sequencing (NGS) Tests market revenue by segment and market outlooks from 2015-2030.

Market level data on units, average selling prices and market values

Reasons to buy
The model will enable you to:

Understand the impact of COVID-19 on Next Generation Sequencing (NGS) Tests market.

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving Next Generation Sequencing (NGS) Tests market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Next Generation Sequencing (NGS) Tests market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track device sales in the global and country-specific Next Generation Sequencing (NGS) Tests market from 2015-2030.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Companies mentioned
Illumina Inc

Thermo Fisher Scientific Inc

Qiagen NV

Agilent Technologies Inc

New England Biolabs Inc

Others